Previous close | 96.10 |
Open | 0.00 |
Bid | 97.80 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 607,744 |
Market cap | 347.503M |
Beta (5Y monthly) | 1.07 |
PE ratio (TTM) | 12.23 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.00 (0.42%) |
Ex-dividend date | 04 Jan 2024 |
1y target est | N/A |
Insight into Baillie Gifford (Trades, Portfolio)'s Latest 13F Filing and Its Impact on Key Holdings
On March 1, 2024, Baillie Gifford (Trades, Portfolio), a renowned investment management firm, made a notable addition to its investment portfolio by acquiring 7,560,929 shares of Mobileye Global Inc (NASDAQ:MBLY), a leader in autonomous driving technologies. This transaction increased Baillie Gifford (Trades, Portfolio)'s total holdings in the company to 15,985,212 shares, reflecting a significant trade impact of 0.16% on its portfolio.
Baillie Gifford (Trades, Portfolio), the renowned investment management firm, has recently expanded its investment portfolio by adding a significant number of shares in Sana Biotechnology Inc (NASDAQ:SANA). This move underscores the firm's confidence in the biotechnology company's growth potential. On February 1, 2024, Baillie Gifford (Trades, Portfolio) acquired an additional 210,603 shares of Sana Biotechnology, reflecting a 2.07% change in their holdings and bringing the total shares owned to 10,360,620.